fluoxetine has been researched along with Body Rocking in 7 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the efficacy of fluoxetine for reducing the frequency and severity of obsessive-compulsive behaviors in autism spectrum disorders." | 9.30 | Effect of Fluoxetine on Obsessive-Compulsive Behaviors in Children and Adolescents With Autism Spectrum Disorders: A Randomized Clinical Trial. ( Dossetor, D; Granich, J; Hazell, P; Kohn, M; Lee, KJ; Marraffa, C; Mouti, A; O'Sullivan, M; Orsini, F; Reddihough, DS; Santosh, P; Silove, N; Whitehouse, AJO; Wray, J, 2019) |
| "Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that reduces obsessive-compulsive symptoms." | 6.94 | The SOFIA Study: Negative Multi-center Study of Low Dose Fluoxetine on Repetitive Behaviors in Children and Adolescents with Autistic Disorder. ( Arnold, LE; Attalla, A; Bregman, JD; Cartwright, C; Childress, A; Chugani, H; Frazier, J; Ginsberg, L; Handen, BL; Hendren, R; Herscu, P; King, B; Kolevzon, A; Melmed, R; Minshew, N; Mintz, M; Murphy, T; Owley, T; Sikich, L; Snape, MF, 2020) |
| "To determine the efficacy of fluoxetine for reducing the frequency and severity of obsessive-compulsive behaviors in autism spectrum disorders." | 5.30 | Effect of Fluoxetine on Obsessive-Compulsive Behaviors in Children and Adolescents With Autism Spectrum Disorders: A Randomized Clinical Trial. ( Dossetor, D; Granich, J; Hazell, P; Kohn, M; Lee, KJ; Marraffa, C; Mouti, A; O'Sullivan, M; Orsini, F; Reddihough, DS; Santosh, P; Silove, N; Whitehouse, AJO; Wray, J, 2019) |
| "Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that reduces obsessive-compulsive symptoms." | 2.94 | The SOFIA Study: Negative Multi-center Study of Low Dose Fluoxetine on Repetitive Behaviors in Children and Adolescents with Autistic Disorder. ( Arnold, LE; Attalla, A; Bregman, JD; Cartwright, C; Childress, A; Chugani, H; Frazier, J; Ginsberg, L; Handen, BL; Hendren, R; Herscu, P; King, B; Kolevzon, A; Melmed, R; Minshew, N; Mintz, M; Murphy, T; Owley, T; Sikich, L; Snape, MF, 2020) |
| "Fluoxetine treatment, compared to placebo, resulted in significantly greater improvement in repetitive behaviors, according to both the Yale-Brown compulsion subscale and CGI rating of obsessive-compulsive symptoms, as well as on the CGI overall improvement rating." | 2.77 | A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. ( Anagnostou, E; Chaplin, W; Ferretti, CJ; Hollander, E; Settipani, C; Soorya, L; Swanson, E; Taylor, BP; Wasserman, S, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Reddihough, DS | 1 |
| Marraffa, C | 1 |
| Mouti, A | 1 |
| O'Sullivan, M | 1 |
| Lee, KJ | 1 |
| Orsini, F | 1 |
| Hazell, P | 1 |
| Granich, J | 1 |
| Whitehouse, AJO | 1 |
| Wray, J | 1 |
| Dossetor, D | 1 |
| Santosh, P | 1 |
| Silove, N | 1 |
| Kohn, M | 1 |
| Herscu, P | 1 |
| Handen, BL | 1 |
| Arnold, LE | 1 |
| Snape, MF | 1 |
| Bregman, JD | 1 |
| Ginsberg, L | 1 |
| Hendren, R | 1 |
| Kolevzon, A | 1 |
| Melmed, R | 1 |
| Mintz, M | 1 |
| Minshew, N | 1 |
| Sikich, L | 1 |
| Attalla, A | 1 |
| King, B | 1 |
| Owley, T | 1 |
| Childress, A | 1 |
| Chugani, H | 1 |
| Frazier, J | 1 |
| Cartwright, C | 1 |
| Murphy, T | 1 |
| Haller, J | 1 |
| Nagy, R | 1 |
| Toth, M | 1 |
| Pelczer, KG | 1 |
| Mikics, E | 1 |
| Hollander, E | 1 |
| Soorya, L | 1 |
| Chaplin, W | 1 |
| Anagnostou, E | 1 |
| Taylor, BP | 1 |
| Ferretti, CJ | 1 |
| Wasserman, S | 1 |
| Swanson, E | 1 |
| Settipani, C | 1 |
| Emslie, GJ | 1 |
| Wennemer, HK | 1 |
| Kornetsky, C | 1 |
| Granana, N | 1 |
| Tuchman, RF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.[NCT00515320] | Phase 3 | 158 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for fluoxetine and Body Rocking
| Article | Year |
|---|---|
Effect of Fluoxetine on Obsessive-Compulsive Behaviors in Children and Adolescents With Autism Spectrum Disorders: A Randomized Clinical Trial.
Topics: Adolescent; Anxiety; Autism Spectrum Disorder; Child; Confounding Factors, Epidemiologic; Female; Fl | 2019 |
The SOFIA Study: Negative Multi-center Study of Low Dose Fluoxetine on Repetitive Behaviors in Children and Adolescents with Autistic Disorder.
Topics: Adolescent; Autistic Disorder; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Bli | 2020 |
A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders.
Topics: Adolescent; Adult; Child; Child Development Disorders, Pervasive; Double-Blind Method; Female; Fluox | 2012 |
4 other studies available for fluoxetine and Body Rocking
| Article | Year |
|---|---|
NR2B subunit-specific NMDA antagonist Ro25-6981 inhibits the expression of conditioned fear: a comparison with the NMDA antagonist MK-801 and fluoxetine.
Topics: Animals; Ataxia; Disease Models, Animal; Dizocilpine Maleate; Electroshock; Excitatory Amino Acid An | 2011 |
Are adults just big children?
Topics: Child Development Disorders, Pervasive; Female; Fluoxetine; Humans; Male; Selective Serotonin Reupta | 2012 |
Fluoxetine blocks expression but not development of sensitization to morphine-induced oral stereotypy in rats.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Dopamine; Fluoxetine; Male; Morphine; Motor Activity; | 1999 |
A child with severe head banging.
Topics: Autistic Disorder; Child; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Selective Seroton | 1999 |